Form 8-K - Current report:
SEC Accession No. 0001698530-25-000017
Filing Date
2025-03-18
Accepted
2025-03-18 16:09:17
Documents
15
Period of Report
2025-03-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xcur-20250318.htm   iXBRL 8-K 25596
2 EX-99.1 a8kye2024exhibit991.htm EX-99.1 75621
6 exicureimage1a10a.gif GRAPHIC 2794
  Complete submission text file 0001698530-25-000017.txt   235789

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xcur-20250318.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xcur-20250318_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xcur-20250318_pre.xml EX-101.PRE 12512
17 EXTRACTED XBRL INSTANCE DOCUMENT xcur-20250318_htm.xml XML 2706
Mailing Address 2430 N. HALSTED ST. CHICAGO IL 60614
Business Address 2430 N. HALSTED ST. CHICAGO IL 60614 847-673-1700
EXICURE, INC. (Filer) CIK: 0001698530 (see all company filings)

EIN.: 815333008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39011 | Film No.: 25748347
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)